Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

Published 2012 View Full Article

Authors

Keywords

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Volume 18, Issue 9, Pages 1455-1461

Publisher

Elsevier BV

Online

2012-03-25

DOI

10.1016/j.bbmt.2012.03.010

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Publish scientific posters with Peeref

Create your own webinar